https://doi.org/10.55788/3210a094
“FasTCAR GC012F is a CAR-T therapy that targets both BCMA and CD19 in order to establish fast, deep, and durable responses in patients with MM,” explained Prof. Juan Du (Shanghai Chang Zheng Hospital, China). With a time from isolation until freezing of only 22–36 hours, the current therapy establishes a fast vein-to-vein time, potentially eliminating the need for a bridging therapy prior to CAR-T infusion, which is often needed in conventional CAR-T therapy. The current, open-label, single arm, investigator-initiated trial subjected 28 patients with heavily pre-treated (≥3 lines of therapy) RRMM to GC012F dual CAR-T therapy. Safety was the primary endpoint of this study. Of note, 89% of the patients had a high-risk profile.
According to Prof. Du, the safety profile of the CAR-T therapy was favourable. Grade ≥3 haematologic adverse events ranged from 36% for anaemia to 82% for neutropenia. The cases of cytokine release syndrome were mostly low grade (0–2: 93%) and only 2 patients experienced a grade 3 cytokine release syndrome event. No cases of immune effector cell-associated neurotoxicity syndrome were reported.
In total, an impressive 89.3% of the patients responded to the therapy, with 75% of the patients displaying a minimal residual disease (MRD) complete response or stringent complete response and 86% of the patients demonstrating a very good partial response (VGPR) or better. In addition, after a median follow-up of 6.3 months, the median duration of response was not reached.
Prof. Du summarised that the updated results of this first-in-human study assessing FasTCAR GC012F dual CAR-T therapy showed very promising activity in a heavily pre-treated, high-risk population of patients with RRMM, with a favourable safety profile. “Fast, deep, and durable responses were achieved with this novel CAR-T therapy.”
- Du J, et al. Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). Abstract 8005, ASCO 2022 Annual Meeting, 3–7 June, Chicago, IL, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Exploratory treatment options fail in ccRCC Next Article
Novel first-line treatment option for mantle cell lymphoma »
« Exploratory treatment options fail in ccRCC Next Article
Novel first-line treatment option for mantle cell lymphoma »
Table of Contents: ASCO 2022
Featured articles
Breast Cancer
Sacituzumab govitecan meets primary endpoint
Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer
Practice-changing results of T-DXd in HER2-low breast cancer
SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer
Metastasis-directed therapy fails in oligometastatic breast cancer
Analysis by residual cancer burden further clarifies effect of pembrolizumab
Contribution of metastatic therapies on mortality reduction in breast cancer
Radiotherapy may be omitted in breast cancer patients
Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer
7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups
Lung Cancer
Additional tiragolumab does not help patients with untreated small cell lung cancer
Success for serplulimab plus chemotherapy in small cell lung cancer
Adagrasib safe and clinically active in non-small cell lung cancer
Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer
Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer
Melanoma
First results on distant metastasis-free survival in stage II melanoma
Higher response rates for concurrent triple therapy versus sequential therapy in melanoma
Genitourinary Cancers
Exploratory treatment options fail in ccRCC
Adjuvant everolimus did not benefit high-risk renal cell carcinoma
Cabozantinib fails as first-line maintenance therapy in urothelial cancer
177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC
Enzalutamide performs well in metastatic hormone-sensitive prostate cancer
Haematologic Malignancies
Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma
Novel first-line treatment option for mantle cell lymphoma
Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma
Gastrointestinal Cancers
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer
Spectacular results for dostarlimab in mismatch repair deficient rectal cancer
Triplet chemotherapy beats doublet chemotherapy in colorectal cancer liver metastases
To resect or not to resect primary tumours in stage IV colon cancer?
Novel treatment option for KRAS wildtype pancreatic cancer
Gynaecological Cancers
Primary results of rucaparib in ovarian cancer
Trabectedin not superior to chemotherapy in recurrent epithelial ovarian cancer
Encouraging results of relacorilant in ovarian cancer
Miscellaneous Topics
Bacterial decolonisation effective against radiation dermatitis
New standard-of-care for cisplatin-ineligible locally advanced head and neck squamous cell carcinoma
Ifosfamide is likely to be the go-to therapy in recurrent Ewing sarcoma
Dabrafenib plus trametinib candidates for standard-of-care in BRAF V600-mutated paediatric low-grade glioma
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy